Key Points
-
Pfizer has regrouped in the GLP‑1 space and is now working on a long‑acting drug option.
-
The company’s update on the drug’s development progress suggests it can compete with GLP‑1 drugs from Eli Lilly and Novo Nordisk.
Human medication adherence is notoriously low, hovering around 50% for long‑term treatments. This poses a major hurdle for GLP‑1 weight‑loss therapies that typically require daily or weekly dosing for life. Pfizer (NYSE: PFE) believes a more convenient regimen could give it a competitive edge.
Pfizer trails the GLP‑1 pack
Novo Nordisk launched the first GLP‑1 weight‑loss injection, Wegovy, followed by Eli Lilly’s Zepbound and Mounjaro, which proved more effective and quickly captured market leadership. Pfizer initially abandoned its own GLP‑1 candidate and later acquired a promising technology to develop a new option.
Image source: Getty Images.
Pfizer’s GLP‑1 drug isn’t on the market yet
Like any pharmaceutical, Pfizer’s Berobenatide must clear regulatory approval before reaching patients. The latest update comes from a Phase III trial, indicating the drug is still far from commercialization. Nevertheless, early data suggest Berobenatide delivers weight‑loss results comparable to or better than existing GLP‑1 therapies, while requiring only monthly administration—a potential boon for adherence.
The prospect of similar efficacy combined with a less frequent dosing schedule could position Pfizer as a viable contender in the GLP‑1 arena, despite its late entry. Competitors such as Novo Nordisk and Eli Lilly are not idle, and further innovations from them are likely. However, obesity affects a large population, creating room for multiple effective treatments. Consumers and clinicians will choose the regimen that best fits individual needs.
Given the positive Phase III signals for Berobenatide, it may be only a matter of time before Pfizer introduces a user‑friendly GLP‑1 option, offering patients a therapy that is easier to stick with over the long term.
